RoL nr 247 maj 2024

Referenser

Kan saliv från giftiga ödlor bromsa ökningen av obesitas?

1. Phelps NH, Singleton RK, Zhou B, Heap RA, Mishra A, Bennett JE, m.fl. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. The Lancet. mars 2024;403(10431):1027–50.

2. World Obesity Atlas 2023 [Internet]. https://www.worldobesity.org/. Tillgänglig vid: https://www.worldobesity.org/

3. Aronne LJ, Hall KD, M. Jakicic J, Leibel RL, Lowe MR, Rosenbaum M, m.fl. Describing the Weight-Reduced State: Physiology, Behavior, and Interventions. Obesity [Internet]. april 2021 [citerad 16 april 2024];29(S1). Tillgänglig vid: https://onlinelibrary.wiley.com/doi/10.1002/oby.23086

4. Holst JJ, Ørskov C, Vagn Nielsen O, Schwartz TW. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett. 26 januari 1987;211(2):169–74.

5. Baggio LL, Drucker DJ. Biology of Incretins: GLP-1 and GIP. Gastroenterology. maj 2007;132(6):2131–57.

6. Brown JC, Mutt V, Pederson RA. Further purification of a polypeptide demonstrating enterogastrone activity. J Physiol. juli 1970;209(1):57–64.

7. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 01 februari 1998;101(3):515–20.

8. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol-Endocrinol Metab. 01 september 1996;271(3):E458–64.

9. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 01 januari 1993;91(1):301–7.

10. Exendin-4: From lizard to laboratory...and beyond [Internet]. National Institute on Ageing. Tillgänglig vid: https://www.nia.nih.gov/news/exendin-4-lizard-laboratory-and-beyond

11. Nauck MA. The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefit-risk relationship. Metabolism. februari 2020;103:154031.

12. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. april 2021;46:101102.

13. Secher A, Jelsing J, Baquero AF, Hecksher-Sørensen J, Cowley MA, Dalbøge LS, m.fl. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 01 oktober 2014;124(10):4473–88.

14. Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-Rønne J, Alanentalo T, Baquero AF, m.fl. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 26 mars 2020;5(6):e133429.

15. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, m.fl. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 21 juli 2022;387(3):205–16.

16. Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, m.fl. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. oktober 2022;28(10):2083–91.

17. Årsrapport SOReg 2022 Del 2 [Internet]. SOReg; Tillgänglig vid: https://www.ucr.uu.se/soreg/component/edocman/arsrapport-soreg-2022-del-2/viewdocument/2160?Itemid=

18. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, m.fl. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 14 december 2023;389(24):2221–32.

19. U.S. Food and Drug administration. FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight [Internet]. Tillgänglig vid: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or

20. Caro R, Samsel D, Savel P. Is there sustained weight loss after discontinuation of GLP-1 agonist for obesity treatment? Evid-Based Pract. maj 2023;26(5):7–8.

21. European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2024 [Internet]. Tillgänglig vid: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024

CLINT – centrum för läkemedelsinformation i T-län Dosering av enalapril, bisoprolol och metoprolol en eller två gånger dagligen?

1. Marte F, Dersnah GD, Cassagnol M. Enalaprilat. I: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [citerad 12 december 2023]. Tillgänglig vid: http://www.ncbi.nlm.nih.gov/books/NBK534299/

2. Gomez HJ, Cirillo VJ, Irvin JD. Enalapril: a review of human pharmacology. Drugs. 1985;30 Suppl 1:13– 24.

3. Enalapril Accord - FASS Vårdpersonal [Internet]. [citerad 08 december 2023]. Tillgänglig vid: https://www.fass.se/LIF/product?userType=0&nplId=20200102000173

4. Leopold G, Ungethüm W, Pabst J, Simane Z, Bühring KU, Wiemann H. Pharmacodynamic profile of bisoprolol, a new beta 1-selective adrenoceptor antagonist. Br J Clin Pharmacol. september 1986;22(3):293–300.

5. Bisoprolol Accord - FASS Vårdpersonal [Internet]. [citerad 08 december 2023]. Tillgänglig vid: https://www.fass.se/LIF/product?userType=0&nplId=20150501000147

6. Morris J, Awosika AO, Dunham A. Metoprolol. I: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [citerad 18 december 2023]. Tillgänglig vid: http://www.ncbi.nlm.nih.gov/books/NBK532923/

7. Metoprolol Sandoz - FASS Vårdpersonal [Internet]. [citerad 11 december 2023]. Tillgänglig vid: https://www.fass.se/LIF/product?userType=0&nplId=20041011000010#indication